RemeGen Co

RemeGen Co Accounts Payable

The Accounts Payable of RemeGen Co (688331.SS) as of Oct 26, 2026 is 285.85 M CNY. In the previous year, Accounts Payable was 162.25 M CNY — a change of 76.18% (higher).

Accounts Payable

285.85 MCNY

YoY

76.18%

Last updated:

Accounts Payable of RemeGen Co is 2025 285.85 M CNY. Accounts Payable of RemeGen Co was 2024 162.25 M CNY. It decreases by 76.18% higher compared to the previous year.

The RemeGen Co Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
16.75 M CNY
Jan 1, 2019
67.70 M CNY
Jan 1, 2020
62.65 M CNY
Jan 1, 2021
159.26 M CNY
Jan 1, 2022
221.69 M CNY
Jan 1, 2023
139.33 M CNY
Jan 1, 2024
162.25 M CNY
Jan 1, 2025
285.85 M CNY
The RemeGen Co Accounts Payable history
YEARAccounts PayableYoY
285.85 MCNY+76.18%
162.25 MCNY+16.45%
139.33 MCNY-37.15%
221.69 MCNY+39.20%
159.26 MCNY+154.22%
62.65 MCNY-7.46%
67.70 MCNY+304.28%
16.75 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Accounts Payable of RemeGen Co is 285.85 M CNY in 2025.

Accounts Payable of RemeGen Co changed from 162.25 M CNY to 285.85 M CNY, representing a 76.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RemeGen Co

All Key Metrics — RemeGen Co